Establishment Labs (NASDAQ:ESTA) PT Raised to $65.00

Establishment Labs (NASDAQ:ESTA) had its price target hoisted by stock analysts at BTIG Research from $62.00 to $65.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target would indicate a potential upside of 52.83% from the stock’s previous close.

ESTA has been the subject of several other reports. Stephens reiterated an “overweight” rating and set a $68.00 target price on shares of Establishment Labs in a research report on Wednesday, August 7th. JPMorgan Chase & Co. dropped their target price on shares of Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Finally, Citigroup lifted their target price on shares of Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Establishment Labs presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.83.

Establishment Labs Price Performance

ESTA stock opened at $42.53 on Monday. The firm has a 50 day moving average of $42.59 and a 200-day moving average of $46.75. The company has a current ratio of 4.44, a quick ratio of 2.91 and a debt-to-equity ratio of 4.30. Establishment Labs has a 12 month low of $16.96 and a 12 month high of $60.12. The firm has a market capitalization of $1.17 billion, a P/E ratio of -13.15 and a beta of 1.20.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. The firm had revenue of $44.12 million during the quarter, compared to the consensus estimate of $43.10 million. During the same quarter last year, the business posted ($0.65) earnings per share. Establishment Labs’s revenue was down 9.2% compared to the same quarter last year. As a group, sell-side analysts predict that Establishment Labs will post -2.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

A number of hedge funds have recently made changes to their positions in ESTA. Hood River Capital Management LLC bought a new stake in shares of Establishment Labs in the 2nd quarter worth approximately $43,000. Nkcfo LLC purchased a new position in shares of Establishment Labs in the second quarter worth $227,000. Concurrent Investment Advisors LLC purchased a new position in shares of Establishment Labs in the first quarter worth $263,000. SG Americas Securities LLC purchased a new position in shares of Establishment Labs in the second quarter worth $303,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in shares of Establishment Labs in the second quarter worth $373,000. 72.91% of the stock is currently owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.